| Fund ID | 805-9153149946 |
| Fund type | Venture Capital Fund |
| 3(c)(1) exclusion | No |
| 3(c)(7) exclusion | Yes |
| Master fund | No |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | Yes |
| Annual audit | Yes |
| Prepared per GAAP | Yes |
| Sub-advised | No |
| % of assets independently valued | 47% |
| Owned by the adviser or related persons | 7% |
| Owned by funds of funds | 17% |
| Owned by non-U.S. persons | 46% |
| Fund | Type | Gross assets |
|---|---|---|
| Redco II Master Fund, L.P. | Hedge | $1.59B |
| Redmile Biopharma Investments III, L.P. | Private Equity | $972.2M |
| Redmile Capital Offshore II Master Fund, Ltd. | Hedge | $845.8M |
Redmile Biopharma Investments II, L.P. reports $657.6 million in gross assets, among the top 11% of private funds by size.
The stated minimum investment is $5 million.
Redmile Biopharma Investments II, L.P. is managed by Redmile Group, LLC.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.